tiprankstipranks
Advertisement
Advertisement

IMTX Stock Latest News

Immatics reports Q1 EPS (43c), consensus (44c)
The FlyImmatics reports Q1 EPS (43c), consensus (44c)
12d ago
IMTX
Immatics Widens Q1 2026 Loss as Collaboration Revenue Drops, R&D Spend Climbs
PremiumCompany Announcements
Immatics Widens Q1 2026 Loss as Collaboration Revenue Drops, R&D Spend Climbs
12d ago
6K
IMTX
Immatics initiated with a Buy at TD Cowen
PremiumThe Fly
Immatics initiated with a Buy at TD Cowen
26d ago
IMTX
Immatics Secures Four High-Profile Oral Slots for PRAME and Bispecific Programs at 2026 ASCO
PremiumCompany Announcements
Immatics Secures Four High-Profile Oral Slots for PRAME and Bispecific Programs at 2026 ASCO
1M ago
6K
IMTX
Immatics Highlights PRAME-Targeted Cell Therapy Remission in Pediatric Kidney Cancer, Plans Pediatric Trial Expansion
PremiumCompany Announcements
Immatics Highlights PRAME-Targeted Cell Therapy Remission in Pediatric Kidney Cancer, Plans Pediatric Trial Expansion
1M ago
6K
IMTX
Immatics abstract accepted for late-breaking poster presentation at AACR meeting
PremiumThe FlyImmatics abstract accepted for late-breaking poster presentation at AACR meeting
1M ago
IMTX
Immatics assumed with a Buy at Jefferies
Premium
The Fly
Immatics assumed with a Buy at Jefferies
2M ago
IMTX
Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance
Premium
Company Announcements
Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance
3M ago
6K
IMTX
Immatics sees cash runway into 2028
PremiumThe Fly
Immatics sees cash runway into 2028
3M ago
IMTX
Immatics reports FY25 EPS (EUR 1.61) vs. EUR 0.14 last year
PremiumThe Fly
Immatics reports FY25 EPS (EUR 1.61) vs. EUR 0.14 last year
3M ago
IMTX
Immatics price target raised to $25 from $23 at Mizuho
PremiumThe Fly
Immatics price target raised to $25 from $23 at Mizuho
3M ago
IMTX
Immatics’ treatment of Stage II and higher CM granted FDA orphan designation
PremiumThe Fly
Immatics’ treatment of Stage II and higher CM granted FDA orphan designation
3M ago
IMTX
Immatics Publishes Updated PRAME-Focused Investor Presentation on January 12, 2026
PremiumCompany AnnouncementsImmatics Publishes Updated PRAME-Focused Investor Presentation on January 12, 2026
4M ago
6K
IMTX
Immatics price target raised to $17 from $14 at BofA
Premium
The Fly
Immatics price target raised to $17 from $14 at BofA
5M ago
IMTX
Immatics Reveals Promising Results from IMA203CD8 Phase 1a Trial
Premium
Company Announcements
Immatics Reveals Promising Results from IMA203CD8 Phase 1a Trial
5M ago
6K
IMTX
Immatics presents IMA203CD8 PRAME cell therapy data at ESMO-IO Congress
PremiumThe Fly
Immatics presents IMA203CD8 PRAME cell therapy data at ESMO-IO Congress
5M ago
IMTX
Immatics Completes $116.5 Million Share Offering to Boost R&D
PremiumCompany Announcements
Immatics Completes $116.5 Million Share Offering to Boost R&D
6M ago
6K
IMTX
Immatics announces offering of 12.5M ordinary shares
PremiumThe Fly
Immatics announces offering of 12.5M ordinary shares
6M ago
IMTX
Immatics N.V. Reports Q3 2025 Financial Results and Progress
PremiumCompany Announcements
Immatics N.V. Reports Q3 2025 Financial Results and Progress
6M ago
IMTX
Immatics price target raised to $23 from $19 at Mizuho
PremiumThe FlyImmatics price target raised to $23 from $19 at Mizuho
6M ago
IMTX
Immatics price target raised to $19 from $16 at Guggenheim
Premium
The Fly
Immatics price target raised to $19 from $16 at Guggenheim
6M ago
IMTX
Morning Movers: E.W. Scripps surges after report of Sinclair takeover interest
Premium
The Fly
Morning Movers: E.W. Scripps surges after report of Sinclair takeover interest
6M ago
SEE
SSP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >